Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments as of March 2024
MARA Rating Company
December 16, 2025
Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
